Objective:
To simplify billing and reimbursement for Epioxa, a corneal cross-linking therapy for keratoconus, while enhancing market access.
Approach:
- The J-code aims to enhance payer acceptance and reimbursement workflows.
- Epioxa is indicated for epithelium-on corneal collagen cross-linking in adults and pediatric patients aged 13 and older.
- The therapy avoids epithelial removal, reducing pain and recovery time compared to traditional methods.
- Common adverse reactions include conjunctival hyperemia, corneal haze, photophobia, punctate keratitis, eye pain, irritation, tearing, and transient reduction in visual acuity.
- Reimbursement gains depend on individual payer adoption of the new code.
- Common adverse reactions include conjunctival hyperemia, corneal haze, and transient visual acuity reduction.
Key Findings:
Interpretation:
The J-code is expected to improve market access and patient care for keratoconus, a condition that is often underdiagnosed and under-treated, potentially leading to better outcomes.
Limitations:
Conclusion:
The CMS decision strengthens the infrastructure for Epioxa's rollout in the US, potentially improving access for patients and surgeons.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
